Axsome Therapeutics/$AXSM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Axsome Therapeutics
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Ticker
$AXSM
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
712
ISIN
US05464T1043
Website
AXSM Metrics
BasicAdvanced
$5.5B
-
-$5.77
0.45
-
Price and volume
Market cap
$5.5B
Beta
0.45
52-week high
$139.13
52-week low
$72.21
Average daily volume
649K
Financial strength
Current ratio
2.028
Quick ratio
1.895
Long term debt to equity
392.749
Total debt to equity
393.602
Interest coverage (TTM)
-30.21%
Profitability
EBITDA (TTM)
-230.961
Gross margin (TTM)
91.49%
Net profit margin (TTM)
-64.39%
Operating margin (TTM)
-55.36%
Effective tax rate (TTM)
-0.03%
Revenue per employee (TTM)
$610,000
Management effectiveness
Return on assets (TTM)
-26.18%
Return on equity (TTM)
-282.16%
Valuation
Price to revenue (TTM)
12.54
Price to book
103.83
Price to tangible book (TTM)
-1,328.24
Price to free cash flow (TTM)
-45.607
Free cash flow yield (TTM)
-2.19%
Free cash flow per share (TTM)
-246.10%
Growth
Revenue change (TTM)
72.16%
Earnings per share change (TTM)
-9.68%
3-year earnings per share growth (CAGR)
15.74%
10-year earnings per share growth (CAGR)
25.27%
What the Analysts think about AXSM
Analyst ratings (Buy, Hold, Sell) for Axsome Therapeutics stock.
Bulls say / Bears say
Axsome's flagship product, AUVELITY, has demonstrated strong market adoption, with prescriptions increasing by approximately 17% quarter-over-quarter in Q3 2024, indicating robust demand and potential for sustained revenue growth. (Investing.com)
The company's pipeline includes promising candidates like AXS-05 for Alzheimer's disease agitation and AXS-07 for acute migraines, with analysts projecting peak sales of up to $1.2 billion for AXS-05, suggesting significant future revenue streams. (Investing.com)
Analysts have a consensus 'Strong Buy' rating for AXSM stock, with a 12-month price target of $171.65, representing a potential upside of approximately 62.79% from the current price. (StockAnalysis.com)
Axsome reported a net loss of $287.22 million in 2024, a 20.1% increase from the previous year, indicating ongoing financial challenges despite revenue growth. (StockAnalysis.com)
The company's debt-to-equity ratio stands at 86.42%, suggesting a high level of leverage that could pose risks if revenue growth does not meet expectations. (TipRanks.com)
Despite strong revenue growth, Axsome's return on equity (ROE) is -5.04%, reflecting inefficiencies in generating profit from shareholders' equity. (TipRanks.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
AXSM Financial Performance
Revenues and expenses
AXSM Earnings Performance
Company profitability
AXSM News
AllArticlesVideos
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4
GlobeNewsWire·1 week ago
Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21
GlobeNewsWire·2 weeks ago
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Axsome Therapeutics stock?
Axsome Therapeutics (AXSM) has a market cap of $5.5B as of July 18, 2025.
What is the P/E ratio for Axsome Therapeutics stock?
The price to earnings (P/E) ratio for Axsome Therapeutics (AXSM) stock is 0 as of July 18, 2025.
Does Axsome Therapeutics stock pay dividends?
No, Axsome Therapeutics (AXSM) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Axsome Therapeutics dividend payment date?
Axsome Therapeutics (AXSM) stock does not pay dividends to its shareholders.
What is the beta indicator for Axsome Therapeutics?
Axsome Therapeutics (AXSM) has a beta rating of 0.45. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.